This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wolf Haldenstein Announces Investigation Of Atossa Genetics, Inc.

The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Atossa Genetics, Inc. (“Atossa” or the “Company”) (NASDAQ:ATOS) and certain of its officers and directors in connection with allegations that the Company and certain of its officers and directors made materially false and misleading statements regarding its compliance with FDA rules and regulations, including Section 510(k) of the Food, Drug and Cosmetic Act.

In particular, the Company misrepresented or failed to disclose that (1) it was required to provide premarket notification to the FDA when it materially altered the design of its ForeCYTE Breast Health Test and Mammary Aspirate Specimen Cytology Test (“MASCT”); (2) the Company improperly marketed its devices by using certain promotional claims to market the ForeCYTE Breast Health Test and MASCT device; (3) the Company was in violation of FDA Good Manufacturing Practices regulations; and (4) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.

On February 25, 2013, the Company disclosed that it received a warning letter from the FDA regarding its MASCT System and MASCT System Collection Test (together, the “System”). Specifically, in the warning letter, the FDA charged that “the Company changed the System in a manner that require[d] submission of an additional 501(k) notification to the FDA” and raised “certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters.” Then, on October 4, 2013, after the market closed, the Company announced “a voluntary recall to remove the ForeCYTE Breast Health Test and the MASCT device from the market” after receiving the February 25, 2013 warning letter from the FDA.

On this news, the Company’s stock price fell $2.47 per share or more than 46%, to close at $2.85 on October 7, 2013.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs